Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels

European Journal of Clinical Investigation

Volumn 44, Issue 4, 2014, Pages 395-401

  Scharnagl, Hubert ^a   Heuschneider, Christina ^b   Sailer, Sabrina ^b   Kleber, Marcus E ^c   März, Winfried ^a,c,d   Ritsch, Andreas ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

Atherosclerosis; CAD patients; Cholesterol efflux; Cholesteryl ester transfer protein; High density lipoprotein function; Reverse cholesterol transport

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL EFFLUX; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FOLLOW UP; HUMAN; LIFESTYLE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CAD PATIENTS; CHOLESTEROL EFFLUX; CHOLESTERYL ESTER TRANSFER PROTEIN; HIGH-DENSITY LIPOPROTEIN FUNCTION; REVERSE CHOLESTEROL TRANSPORT;

AGED; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ARTERY DISEASE; HUMANS; LIFE STYLE; MACROPHAGES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84895922075     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12248     Document Type: Article

References (25)

1. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
2. Karalis I, Rensen PC, Jukema JW. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Circ Cardiovasc Qual Outcomes 2013;6:360-6.
3. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
4. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30.
5. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
6. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901.
7. Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009;2:26-33.
8. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777-88.
9. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
10. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008;29:2792-9.
11. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20.
12. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010;121:366-74.
13. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35.
14. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-705.
15. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:S1-73.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl 1):S43-8.
18. Ritsch A, Auer B, Foger B, Schwarz S, Patsch JR. Polyclonal antibody-based immunoradiometric assay for quantification of cholesteryl ester transfer protein. J Lipid Res 1993;34:673-9.
19. Ritsch A, Ebenbichler C, Naschberger E, Schgoer W, Stanzl U, Dietrich H et al. Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med 2004;42:247-55.
20. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796-801.
21. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93.
22. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008;197:57-63.
23. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97.
24. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23.
25. Villard EF, El Khoury P, Duchene E, Bonnefont-Rousselot D, Clement K, Bruckert E et al. Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler Thromb Vasc Biol 2012;32:2341-9.